局部化学结构解释精神病临床高风险相关的广泛皮层变薄
该研究整合ENIGMA CHR工作组的大样本汇总数据(1782例CHR,1333例健康对照)与开源PET分子图谱,首次识别精神病风险、转化及核心症状相关皮层变薄的潜在神经化学驱动因素。多线性模型分析显示,局部化学结构显著解释CHR病例对照状态、阴性症状严重程度及未来精神病转化相关的皮层厚度差异(排除药物混杂后)。多巴胺、GABA、谷氨酸、5-羟色胺和去甲肾上腺素的PET图谱一致是CHR和精神病转化中较低皮层厚度的最强预测因子。
要点
- 局部化学结构可解释CHR相关的皮层变薄,单胺能、谷氨酸能和GABA能通路是关键分子机制。
- 多巴胺、GABA、谷氨酸、5-羟色胺和去甲肾上腺素PET图谱是CHR和转化中低皮层厚度的最强预测因子。
- 阴性症状相关皮层变薄由多巴胺、组胺、5-羟色胺和阿片系统图谱解释,组胺贡献对药物暴露敏感。
核心结论
- 特定神经化学系统,特别是单胺能、谷氨酸能和GABA能通路,是与精神病高风险人群皮层变薄相关的关键分子机制。
研究设计与样本
- 研究整合ENIGMA CHR工作组的大样本汇总数据集(N=1782 CHR,N=1333健康对照)与开源PET分子图谱,采用多线性模型分析。
主要发现
- 局部化学结构显著解释CHR病例对照状态、阴性症状严重程度及未来精神病转化相关的皮层厚度差异(排除药物混杂后)。
- 多巴胺、GABA、谷氨酸、5-羟色胺和去甲肾上腺素的PET图谱是CHR和精神病转化中较低皮层厚度的最强预测因子(总优势范围分别为62-69%和58-87%)。
- 单胺能系统的贡献对药物暴露特别敏感(优势范围变化8-23%)。
- 阴性症状相关皮层变薄最佳解释因素为多巴胺、组胺、5-羟色胺和阿片系统PET图谱(总优势范围60-81%),组胺贡献对药物暴露敏感(优势范围变化9-19%)。
临床怎么用
- 研究提示可关注单胺能、谷氨酸能和GABA能通路作为精神病高风险个体皮层变薄的潜在生物标志物。
- 药物暴露可能影响单胺能和组胺系统对皮层变薄的贡献,临床解读时需考虑用药情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Clinical High Risk (CHR) state for psychosis is consistently associated with widespread cortical thinning. However, the underlying mechanisms driving this neuroanatomical phenotype remain poorly understood. Here, we integrated the ENIGMA CHR Working Group's large pooled dataset (N = 1782 CHR, N = 1333 healthy controls) with an open-source PET molecular atlas to identify, for the first time, potential neurochemical drivers of cortical thinning associated with psychosis risk, transition, and its core symptoms. Using multilinear model analysis, we show that local chemoarchitecture significantly explains CT differences associated with CHR case-control status, the severity of negative symptoms, and future psychosis transition after excluding medication confounds. PET-based maps of dopamine, GABA, glutamate, serotonin, and norepinephrine consistently emerged as the strongest predictors of lower CT in CHR and psychosis transition (total dominance range: 62-69% and 58-87%, respectively), with contributions of monoamine systems being especially sensitive to medication exposure (8-23% change in dominance range). Negative symptom-associated cortical thinning was best explained by PET-based maps of dopamine, histamine, serotonin and opioid systems (total dominance range: 60-81%), with contributions of histamine being sensitive to medication exposure (9-19% change in dominance range). Combined, these results uniquely identify specific neurochemical systems - particularly monoaminergic, glutamatergic, and GABAergic pathways - as key molecular mechanisms associated with cortical thinning in people at high risk of developing psychosis.
引用
- Yang X, Agartz I, Andreassen O, et al. Local chemoarchitecture explains widespread lower cortical thickness associated with clinical high risk for psychosis. Mol Psychiatry. 2026. PMID: 41935185. doi:10.1038/s41380-026-03586-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。